

PRESS RELEASE  
05 October 2021



## Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

**Cambridge, UK, 05 October 2021:** Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of *in vivo* reprogramming therapies and transforming the development of *ex vivo* cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a \$33 million USD [Series A](#) funding. Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. In her new role, Louise will lead the advancement of the Company's internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.

Louise has over 20 years' experience in pre-clinical and clinical therapeutic research. Formerly Vice President of Immunology Research at GlaxoSmithKline (GSK), she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. Her roles at GSK included sponsorship of the Immunology Network, hosting external collaborators at GSK on sabbatical to nucleate and develop novel therapeutic concepts, championing in-licensing of assets, and representing GSK on the board of Sitryx. Prior to GSK, Louise led research teams at Boehringer Ingelheim Pharmaceuticals, and Millennium Pharmaceuticals (now Takeda), where she progressed therapeutic candidates targeted at immunology, oncology, and cardiovascular indications with unmet need. Dr. Modis holds a BSc (Biotechnology) from the National University of Ireland, Galway, earned her PhD (Developmental Hematology) at EMBL, Heidelberg, Germany and completed her postdoctoral fellowship at Harvard University, Boston.

**Dr. Darrin M. Disley, OBE, CEO, Mogrify, said:** *"We are delighted to welcome Louise to the Mogrify Executive Team following a global search that considered drug discovery specialists from across Europe and the United States. Louise's domain expertise, intellectual curiosity and passion for developing novel modalities capable of transforming clinical outcomes for patients suffering with degenerative diseases, make her an ideal fit to lead our internal programs through to first-in-human studies."*

**Dr. Louise Modis, Chief Scientific Officer, Mogrify, added:** *"I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective *ex vivo* cell therapies in immuno-oncology. I am particularly enthused by the Company's development of novel *in vivo* therapeutic modalities and the opportunity to progress a number of *in vivo* reprogramming therapies rapidly through development into the clinic."*

For further information about Mogrify's team, please visit:

<https://mogrify.co.uk/team/leadership-team/>

ENDS

## Notes to Editors



*Darrin M. Disley, PhD,  
DSc, OBE CEO, Mogrify*



*Louise Modis, PhD  
Chief Scientific Officer,  
Mogrify*

For high-resolution images please contact Zyme Communications.

### **For further information please contact:**

Mogrify

Darrin M Disley, PhD, OBE

Tel: + 44 (0)1223 734154

Email: [darrin@mogrify.co.uk](mailto:darrin@mogrify.co.uk)

Zyme Communications (media inquiries)

Michelle Ricketts, PhD

Tel: +44 (0)7789 053 885

Email: [michelle.ricketts@zymecommunications.com](mailto:michelle.ricketts@zymecommunications.com)

Westwicke, an ICR Company (investor inquiries)

Stephanie Carrington

Tel: +1 (646) 277-1282

Email: [stephanie.carrington@icrinc.com](mailto:stephanie.carrington@icrinc.com)

*To opt-out from receiving press releases from Zyme Communications please e-mail [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#).*

### **About Mogrify [www.mogrify.co.uk](http://www.mogrify.co.uk)**

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham *et al.*, Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj *et al.*, Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors (or small molecules) and optimal culture conditions required to produce any target human cell type from any source human cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct trans differentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platforms to generate the scalable source of functional cell types required to pioneer a new class of *in vivo* reprogramming therapies and transform the

development of *ex vivo* cell therapies for indications of high unmet clinical need in immuno-oncology, ophthalmology and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth \$39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, as well as the exploration and generation of novel cell-based and *in vivo* reprogramming therapies for broad therapeutic application. Based in Cambridge, UK, the Company has raised over \$40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner, and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Follow Mogrify on Twitter [@Mogrify\\_UK](#) and LinkedIn [@Mogrify](#)